Back to Search Start Over

Palatin Technologies initiates Phase 2 bremelanotide clinical study to treat obesity

Source :
M2 Pharma. June 13, 2024
Publication Year :
2024

Abstract

M2 PHARMA-June 13, 2024-Palatin Technologies initiates Phase 2 bremelanotide clinical study to treat obesity (C)2024 M2 COMMUNICATIONS Palatin Technologies, Inc. (NYSE American: PTN), a US-based biopharmaceutical company developing first-in-class medicines [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
M2 Pharma
Publication Type :
News
Accession number :
edsgcl.797558787